Form 4: AN2 Therapeutics Director Receives Stock Compensation and Discloses Indirect Holdings

Robin Shane Readnour, a director at AN2 Therapeutics, received 9,077 shares of common stock as compensation and disclosed indirect holdings through MGC Venture Partners.

Summary

• Robin Shane Readnour, a director of AN2 Therapeutics, received 9,077 shares of common stock as compensation on December 19, 2024.
• These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy and vest immediately.
• Readnour also reported indirect beneficial ownership of 582,288 shares held by MGC Venture Partners 2018 LP and 652,573 shares held by MGC Venture Partners QP 2018 LP.
• Readnour is a managing partner of MGC Venture Partners 2018 GP, which has shared voting and dispositive power over the shares held by MGC Venture Partners 2018 LP and MGC Venture Partners QP 2018 LP.
• Readnour disclaims beneficial ownership of these shares except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction and disclosure, which is neutral to slightly positive as it aligns director interests with the company.

Positives

• The issuance of shares as compensation aligns director interests with company performance.
• The immediate vesting of shares provides an incentive for continued service.

Risks

• The document does not indicate any specific risks.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when there are changes in beneficial ownership by directors or officers. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The stock compensation is a common practice for directors of publicly traded companies.
• The disclosure of indirect holdings through investment partnerships is also a standard practice.
• The reporting of these transactions is in line with SEC regulations and industry norms.

Stakeholder Impact

• The stock compensation may be viewed positively by shareholders as it aligns director interests with company performance.
• The disclosure of indirect holdings provides transparency to the market.

Key Dates

Keywords

AN2 Therapeutics, director, stock compensation, beneficial ownership, MGC Venture Partners, Form 4, insider trading